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Chapter 1
Introduction
1.1 Background
Prostate cancer is one of the most common cancers, affecting roughly 1 in 5 men
in the USA. Men diagnosed with PC typically have several treatment choices, and
to decide between them, one would need to consider what effect the treatment will
have on various bodily functions. For example, radial prostatecomy is known to
have a fairly strong effect on sexual function level. Other bodily functions of interest
include urinary, bowel, and general physical function. To help the patient make their
decision, it would be very helpful to provide them with a prediction of what their
various function levels would be, should they choose a given treatment.
Typically, each of these functions can be quantified, and are known to change with
time. For example, one can be assigned a sexual function score, and typically one's
sexual function score undergoes a steep drop immediately after surgery, before slowly
recovering to some steady state level. Then, the piece of information that would be of
use to a patient is to offer them, for each treatment and each function, a time series
of the function level, should they undergo the given treatment.
Furthermore, data shows that one's function time series for a given treatment
varies by patient; different patients undergoing the same treatment should expect to,
on average, experience different function time series. For example, patients who are
doing poorly in terms of sexual function before surgery should expect to do worse in
11
the long run than patients who were sexually unhealthy before surgery.
1.2 Goal of Project
Therefore, our goal is to build a predictive model of the personalized function time se-
ries for patients, taking into account patient attributes such as age, race, comorbidity,
and function level prior to treatment.
To help people make decisions, it is not enough to present to a patient a single
most likely estimate of their function time series given a treatment - if one is not
very certain in the prediction, then that information should be communicated to the
patient. Thus, we will take a Bayesian approach to curve prediction that furthermore
utilizes a novel prior structure, reflecting our a priori belief that the more 'extreme'
a patient is, the the more uncertainty there would lie in our predictions for a patient.
1.3 Desirables for Model
We would like our model to be Bayesian, because we want to know how much uncer-
tainty there is in our curve predictions. We want the model to be easily intrepretable
-the parameters of our model should have easy to understand meanings. Finally, we
want to build into our model the belief that the 'average' patient should be predicted
to have a curve that is the 'average' of all the curves in the dataset. Without patient-
specific predictions, a patient would simply look up a study of prostate cancer, and see
on average, how one side effect is affected if he should choose a particular treatment.
In other words, a patient would regard himself as being average, and should expect to
have the average response to treatment. In the case of patient-specific prediction, we
believe the average patient should still map to the average curve. Furthermore, in the
absence of data, we should do as before, and predict all patients to have the average
response. This belief will be encoded in the prior distribution for our Bayesian model.
12
Chapter 2
Exploratory Data Analysis
2.1 Dataset
To build our predictive models, we use a dataset collected by urologists at UCLA,
which has previously been used in publication[2]. This data follows a cohort of roughly
1000 patients who received one of 3 possible treatments - prostatectomy, radiation
therapy, or brachytherapy for a period of 5 years. Surveys were sent at various
time points after treatment that asked patients to assign a functional score in each of
several categories: sexual, bowel, and urinary function, as well as general physical and
mental well being. These scores are between 0 and 100. Several patient attributes
such as age, race, comorbidity count, and PSA level were also recorded for every
patient. Figure 1 shows an example of the average sexual function scores in the entire
dataset after each of 3 treatments.
2.2 General Shape of Function Curves
The very first thing we did was to see on average what the function curves looked like
for different patients, and whether they differed by treatment. Below, for each of the
3 side effects, we plot the aggregate function time series for patients opting for each
treatment.
All of the aggregate curves seem to have a similar shape: an initial instantaneous
13
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drop off in function level, followed by a rise to some steady state function level.
This hints that we should model the curves parametrically, parameterizing the key
attributes of it - the initial drop, the long-term drop, and the rate of function recovery.
Secondly, the treatment chosen does seem to affect the level of initial function drop
and long term function level.
2.3 Dependence of Function Curves on Patient At-
tributes
The second thing we wanted to look at was for a given side effect and treatment,
whether the function curves vary depending on the available attributes. Below, for
each of the 3 side effects, for each of the 6 attributes we have for patients, divide the
dataset into 2 halves, based on the given attribute. We plot the average function time
series for each half of the dataset, to see if there is a difference.
It seems like there is a difference in the curves, depending on various attributes.
However, the attributes seem to be strongly correlated with the pre-treatment func-
tion level. It seems logical that the pre-treatment state would be highly correlated
with the post-treatment function level. To verify this, we make the same plots as be-
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Figure 2-2: Average patient
patient attributes
time series for the 3 side effects, stratified by each of 6
fore, except this time, we stratify the patients by their pre-treatment function level.
Indeed, pre and post-treatment function levels are highly correlated.
We wonder whether after controlling for the pre-treatment state, a patient's at-
tributes still impact their curves. Thus, for each side effect, treatment combination,
for each of the 6 attributes, we made a scatter plot of the attribute vs the change in
side effect function level before treatment and right after treatment (at the 1 month
survey time). There are too many side effect/treatment combinations to display scat-
ter plots for, but below, we choose 3 such combinations and show their associated
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Figure 2-3: Average patient time series for the 3 side effects, stratified by each of 6
patient attributes
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scatter plots.
There is definitely no trend for some attributes, but perhaps for some there is a
slight one.
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Chapter 3
Model Description
3.1 Model Description
Here, we describe the model we will use to model side effect function values. First, we
note that we will use completely independent models for each side effect and treatment
combination. While we did not have to adopt such an approach (for example, a
patient's function might have a patient-specific and treatment-specific component),
we do so for simplicity's sake.
In short, we assume that each patient has a 'true' function curve gi(t), and that
the observed function values g (tj) are normally distributed about gi(tj). The 'true'
function curve will be parameterized by 3 latent parameters, each of which is modelled
with a generalized linear model that depends on patient covariates. In the prior,
the parameters for these 3 geenralized linear models are independent, though in the
posterior, they will become dependent through the observed function values.
3.2 Parametric Form of Curve
Recalling the general function curve shapes from the previous section, we decide the
3 things we want to model of the curve gi(t) are:
1. The long term drop in function value
17
2. The short term drop in function value
3. The rate at which the function value recovers from the initial drop to the long
term value.
Furthermore, we place the following restrictions on the curve:
1. The long term drop in function value is indeed a drop; that is, the long term
function value is less than the pre-treatment function value
2. The short term drop is greater than the long term drop in function value.
3. 'True' function values at all times are between 0 and 1.
With these considerations in mind, we are ready to describe the parameterization
of g(t):
g(t; s, a, b, c)
where
a
b
C
= s(1 - a - b(1 - a)e-'t)
E
E
(0,1)
(0,1)
(0,oo)
" s is the pre-treatment function level
" a is the long term loss in function level, relative to the pre-treatment function
level
" b is the short term loss in function level in excess of the long term loss, expressed
as a portion of the long term function level
18
(3.1)
(3.2)
(3.3)
(3.4)
(3.5)
(3.6)
and
* c is the rate of the function level decays from the short term to long term
function level
Note that the restrictions we place on the curve are enforced by the restrictions
on a, b, c.
3.3 Model for Curve Parameters
Now that we defined how the 'true' function level curve is parameterized, we will define
the models for each of the parameters. As the parameters' ranges are constrained, we
cannot use a standard linear model for the parameters. However, generalized linear
models will suit us perfectly. Furthermore, as a and b have the same range, the models
for a and b will be analogous to each other.
3.3.1 Generalized Linear Model
Standard linear regression models the observed variable Y as coming from a Normal
distribution such that E(Y) is a linear function of the covariate vector X. That
is, Y - N(BX, o-), where a is the standard deviation of Y, and more generally, a
parameter that either directly or indirectly specifies the spread of Y. Generalized
linear regression generalizes linear regression in 2 ways: 1. The observed variable
Y comes from a distribution with a density p(Y) that is not necessarily that of
the normal distribution, and 2. E(Y) is no longer necessarily a linear function of
covariates, but the result of a linear function of covariates that is subsequently sent
through a link function. That is, E(Y) = f(BX), where f is the link function.
Specification of f allows one to control the manner in which the mean response E(Y)
depends on covariates. In particular, it allows one to restrict the range of E(Y).
A Generalized linear model relating the observed variable Y to covariate vector
X thus has 2 components:
e a probability distribution p(Y) parameterized, its mean p = E(Y) and a pa-
rameter # controlling the variance of Y.
19
* a link function f such that y = f(BX + z)
Note that we explicitly allow for a bias term z. For example, linear regression can
be thought of as a generalized linear model where p(Y) = Pnormal(Y; A = it, = 
and the link function f being the identity function.
3.3.2 Model for a
As a must reside in the unit interval, if we are to model a using a GLM, p(a : p, #)
must have zero support outside the unit interval. The Beta distribution is a good
candidate for p(a). In fact, GLM using a beta expression to model the dependent
variable has been studied in detail before[1].
3.3.3 Beta Distribution
This is a continuous distribution with support in (0,1). There are various parameteri-
zations of the Beta distribution. The most common one, for a distribution Beta(a, #)
is as such:
paeta(y; a,#) 0c y - (I - Y)'-1 (3.7
with E(X) = and Var(X) = . However, for GLM, we require p(Y)
to be parameterized by y = E(Y) and some dispersion parameter #. Fortunately,
some properties of the Beta distribution allow for such a parameterization. Firstly, if
we let
pI= (3.8)
1 =(3.9)
a+# +1
we see that a Beta(af, #) random variable has mean y and variance p(1 - pI)#. We
can then solve the above 2 equations for yL and # in terms of a and #. Then, we can
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obtain an alternate parameterization for a Beta random variable p(y; y, #) =
3.3.4 GLM for a
Now, we can describe the model for ai concisely:
ai ~ Beta(pt, #a) (3.10)
p = fa(B"X, + Za) (3.11)
fa( -) 1 _ (3.12)
fa is the link function for the GLM, which we have chosen to be the logistic
function, as pq must be between 0 and 1. We have not described what za will be
yet, but will do so shortly. b is defined analogously to a. We have not defined what
distribution #a follows. For now, the important thing is that #a is shared between
patients, and is between 0 and 1.
3.3.5 GLM for c
Keeping in mind that c > 0, we will let c come from a gamma distribution. The
gamma distribution can be parameterized by its mean y and a shape parameter
k that controls the variance of the distribution. We would like c to come from a
unimodal distribution, which will be the case if k > 1. We model the inverse of
k instead, letting #' = in the traditional gamma distribution parameterization,
keeping in mind that k is between 0 and 1, and is again, shared between patients.
Thus, the model for c is as such:
ci ~Gamma(p!, #') (3.13)
fc(BcXi + zc) (3.14)
fc(x) = e' (3.15)
Once again, we defer specification of the priors for the parameters ze, Bc and #'
21
until later.
3.3.6 Data Normalization and choosing intercepts za, zb, z C
The way we normalize the data and choose the intercept parameters is guided by our
desire in the model that the the 'average' patient should, under our model, expect to
receive the average curve as their 'true' curve, which is a curve for which a, b, c are
equal to the average value of those parameters in our dataset, which we will denote as
a b WewudtewtCh oait
P4 ,, ,u,, p respectively. We would like, for the patient with the average covariate
vector Xpp, E(a) = p and likewise for b and c. We can accomplish by doing the
following:
1. normalize each covariate to have 0 mean and standard deviation 1 across the
dataset
2. Set z' = ga-(p,,)
Looking at the equation for i, one sees that this way, the average patient has a
covariate vector equal to the 0 vector, and receives a value of p14- = o.
3.3.7 Extracting mean population parameters a,, b ,
To calculate these mean parameters, we need to know their values for each patient.
But we don't actually observe patient curve parameters a, b, c, and so we will obtain
them through least squares curve fitting, ensuring that the curve parameters obey
their constraints. More specifically, for each patient i, we want to:
m
minimize -(gl(tj) gi(t; si, aib, c,)) 2
j=1
subject to
ai E (0, 1)
bi (0, 1)
ci E (0, oo)
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For curves where the function value does not drop (or even increases) after treat-
ment, a will be quite small or even 0, and the fitted curve may be flat when the actual
curve rises. However, we view this as unavoidable due to the restrictions of the kinds
of curve we allow in our model.
3.4 Model for observed data
We have described how a patient's true curve g(t; s, a, b, cdepends on 3 latent param-
eters a, b, c and observed pre-treatment value s, and how those 3 parameters depend
on patient covariates and the parameters of the model Ba, Bb, Bc. Now, it remains
to specify how the observed data g*(tj; s, a, b, c) depends on g(tj; a, b, c). We will take
a simplistic model. We will assume that the observed function value at time tj is
normally distributed about the true function value. That is,
g (ti; si, ai, bi, ci) ~ N(gi(tj; si, ai, bi, ci, o-"se) (3.16)
for all patients i and at all measurement times t1 , .. . , tj.
Thus, we are assuming that the observed function values for a patient are con-
ditionally independent of each other given the patient's true curve parameters. In
reality perhaps those observed values might be correlated, but we opt for simplicity
whenever possible.
3.5 Priors for parameters
Thus far, our model contains 7 parameters: 0 = {Ba, B6, Bc, 4a ,b, c, knise}. As
we adopt a Bayesian framework, we must give prior distributions for each of those
parameters P(9; a) where a is a set of hyperparamters.
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3.5.1 Desired prior predictive distribution for a, b, c
To describe what properties we want of P(G; a), it is more useful to describe, before
observing any data, what we want the distribution over g(t; s, a, b, c) to look like. As
g(t; s, a, b, c) is fully described by a, b, c, then what we want to do is, for an test patient
X, describe the prior predictive distributions P(a; a, X), P(b; a, X), P(c; a, X). X
denotes the test sample, not the data that we have yet to observe. These distributions
will of course depend on X. We want P(a; a, X) to be:
1. unimodal, for reasonably values of X
2. roughly centered around p
3. to have larger variance the further X is from the average covariate vector. (since
we are normalizing the data to be mean 0, this means the larger the magnitude
of X, the larger the variance of P(a; a, X).
These same desirables apply to the prior predictive distributions of b and c.
3.5.2 Specifying the Priors for Parameters
We will let the parameters Ba, Bb, Be each follow normal distributions in the prior.
These normal distributions will be be mean zero, and have a diagonal covariance
matrix equal to some scalar multiple of the identity matrix. That is, we will let:
Ba ~ N(0, c1) (3.17)
Bb ~ N(0, cb1) (3.18)
Bc ~ N(0, cI) (3.19)
(3.20)
where c, cbICc are hyperparameters, as they describe prior distributions of model
parameters. We will also let the disperson parameters #a Ob, # ,#cnoise follow expo-
nential distributions truncated at 1. That is, we will let:
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# ~ truncated-exp(Aa, 1) (3.21)
#b ~ truncated-exp(Ab, 1) (3.22)
# ~ truncated-exp(AC, 1) (3.23)
#n"ise truncated-exp(A"*ise, 1) (3.24)
(3.25)
The reason why we choose the prior for these parameters is that we want to
encourage them to be small so that the distributions for a, b, c will have relatively
small variance in the prior. The reason for this is that in general, distributions with
high variances with finite support will not be unimodal, which is a situation we want
to avoid.
Now, we analyze the influence of the hyperparameters Ca and A" on the prior
predictive distribution P(Xla). We will do so in 2 steps:
1. Study how P(pa; Ca, X) depends on X and Ca and choose Ca.
2. Study how P(a; ca, X, A') depends on Aa, once Ca is chosen
3.5.3 Prior Predictive Distribution for [a
Here, we study the prior predictive distribution of jja, the underlying 'true' value of
the parameter a for a patient with covariate vector z. The goal of this section is to
see how our prior belief on what A varies depends on the hyperparameters. We first
claim that in the prior predictive distribution, Aa follows a logit-normal distribution,
whose properties we will now describe.
3.5.4 Logit-Normal Distribution
A logit-normal distribution is a continuous distribution defined on the open interval
(0, 1). A random variable X follows a logit-normal distribution if the transformed
25
random variable logit(X) follows a normal distribution. An equivalent definition
makes the parameterization of a logit-normal distribution clear:
Definition 1. If Y ~ Normal(p, -) , then the transformed random variable X =
logistic(Y) follows a Logit-Normal(I, o) distribution.
Thus, a Logit-Normal distributed random variable X is parameterized using the
mean and standard deviation of the normal distribution that Logit(X) follows.
Key Properties
Applying the change of variable formula to the density function of a Normal(I, o-)
random variable under the logistic transformation, one arrives at the density function
of a Logit-Normal(p, -) random variable:
1 (logit(x) - p')2  1fx(z; p, - = exp - ; x E (, 1) (3.26)
o-v52 20.2 X(1 - X)
Unfortunately, there are no analytical formulas for the mean, variance, or mode
of a logit-normal distribution.
Unimodality
In general, the density of a logit-normal distribution may have either 1 or 2 modes.
For sufficiently large o-, a Logit-Normal(p, -) distribution will have 2 modes - one
near 0 and one near 1. This intuitively makes sense, because a sufficiently diffuse
normal distribution will have significant mass far away from 0, where the slope of the
logistic function is nearly flat. Conversely, for sufficiently small o-, fx (x; i, -) will be
unimodal. This result can be seen analytically.
By taking the derivative of fx (x; y, o-), it can be seen that the modes of fx (x; y, 0-)
occur at x for which the following condition is satisfied:
logit(x) = o.2 (2x - 1) + y (3.27)
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For any y and o, there is always at least 1 x for which this condition is satisfied.
Thus, fx(x; y, o-) always has at least 1 mode. Furthermore, as the slope of logit(x)
is always greater than 1, we see that if o2 < 1, there is exactly 1 x such that the
condition is satisfied, and arrive at the following observation:
Observation 1. If a2 < 1, then fx(x; y, a) is unimodal.
3.5.5 Logit-Normality of Pa in the Prior
The only hyperparameter that #' depends on in the prior is E' = cI. Now, we see
that #L' Ica, the prior predictive distribution of a, follows the logit-normal distribution.
This is because B ~ N(o, E and so Bz N(0, z'Eaz). Then, p,, + Bagi
N(p,,, z' ). Finally, as /i"aca ~ ga(,*, + Bz) and ga was defined to be the
logistic function, we arrive at the following observation:
Observation 2. a ICa ~ Logit-Normal(p;*,, &'), where &a = zEai = Ca _
where we have used the fact that Ea was parameterized by the hyperparameter
ca.
3.5.6 Dependence of Prior Predictive Distribution of pa on
Hyperparameters
For a test sample z, the prior predictive distribution #a ICa is distributed Logit-Normal(ip,, &a),
where * = ga(p,) and &a is as defined in the previous section. Let us first see
how this prior predictive distribution depends on p and &a. In Figure X, we have
plotted for several values of p,, how the prior predictive distribution Aa|Ca depends
on &'. The vertical line denotes the location of p4,
There are several things to note from the figure:
1. As &a approaches 0, Logit-Normal(p"*, &a) converges to the point mass at pap,
Recall that we are normalizing the covariate vectors so that each covariate has
mean 0 and standard deviation 1 over the training data, so that if a test sample
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xFigure 3-1: prior predictive distribution of A'
z is equal to the 'average' patient of the training data, then z = 0. This means
that the more similar a test sample z is to the 'average' patient, the more closer
xz is to 0, the smaller &' is, and thus the more strongly we believe in the prior
that #a is equal to p",,, the average of a in the training data. This is what we
want.
2. If &a < 1, then p(#a; ca) is necessarily unimodal.
might still be unimodal, but not necessarily.
3. As &a increases, the mode of P(f#4; Ca) increases.
mode to remain constant as &a increases, we see
Fortunately, the spread of P(Aa; Ca) also increases,
prior belief over P.
If &a > 1, then f([a; Ca)
While we would like the
this as being unavoidable.
so that we have a weaker
4. The mean of A|ca decreases as &a increases. So the mode and mean exhibit
opposite trends.
In Figure X, we plot how the mode of P(#a; Ca) changes with &a, as p" is held
fixed. We do this for several values of p4.
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3.5.7 Choosing ca and A'
We are ultimately concerned in the prior predictive distribution of d. The previous
analysis informs us that we should choose ca to ensure that &a is less than 1 most of
the time, as mu" is unimodal in those situations. Due to our data renormalization, we
can make the assumption that X follows a multivariate N(O, I) distribution. Then,
to pick ca, one can follow the following steps:
1. Choose a proportion p such that you want proportion p of possible test samples
X to have an unimodal distribution for P(p ICa, X)
2. Calculate (analytically or otherwise) the Ca such that P(&' < 1) = p.
Once ca is chosen, we understand the distribution pQ"a; X, Ca). However, what
we care about is P(a; X, c, Aa). Even if P(p"; c, X) is unimodal, P(a; c, X, Aa) may
not be unimodal if Aa is too small. The reason is that if #a is too large, the variance
of P(a; Ca, X, Aa) will be large even if the variance of P(Ia; X, c&) is small, and large
variances preclude unimodality of distributions. While we cannot fix #a to be small,
we can place a prior on #a that encourages it to be small. As #a follows a (truncated)
exponential distribution with rate parameter A", the larger Aa is, the more likely #a
is to be small. Thus, we choose Aa finding a value such that in P(a; ca, X, A") is
unimodal most of the time.
3.5.8 Prior Predictive Distribution for Ac
Here, we study the prior predictive distribution of #t, the underlying 'true' value of
the parameter c for a patient with covariate vector z. The goal of this section is to
see how our prior belief on what pC varies depends on the hyperparameters. We first
describe the log-normal distribution, because it turns out this is the distribution that
Ac follows a log-normal distribution in the prior.
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Log-Normal Distribution
A log-normal distribution is a continuous distribution defined on the open interval
(0, oo). A random variable X follows a log-normal distribution if the transformed
random variable log(X) follows a normal distribution. An equivalent definition makes
the parameterization of a log-normal distribution clear:
Definition 2. If Y - Normal(p, o 2 ), then the transformed random variable X =
exp(Y) follows a Log-Normal(p, U2) distribution.
Thus, a Log-Normal distributed random variable X is parameterized using the
mean and standard deviation of the normal distribution that log(X) follows.
Key Properties
The density of a Log-Normal(p, a 2) distribution is:
2) 1 x (log(z) - p)2.fx(X; /,ct,) = exp log-) 2 ); X > 0 (3.28)
The log-normal distribution is unimodal regardless of the choice of parameters.
This is suitable for our poses. There are analytical formulas for the mean and mode;
the mean is exp(p + , and the mode is exp(p - c 2). Like in the case of the logit-2)'
normal distribution, neither the mean nor mode are constant as a 2 increases, for fixed
pL. Also, the mode and mean exhibit opposite trends. Finally, as one would expect,
the variance is increasing in a2
Log-Normality of [c in the Prior
The only hyperparameter that fL' depends on is cC. The argument for the log-
normality of ftc is exactly analogous to that for the logit-normality of A'. The prior
predictive distribution of pA, p"|j cC, is distributed gC(/Cp* + Bcz). BC ~ N(0, ccI), and
so Bcz ~ N(0, &c) where dc := '(ccI)z = cc E' z.4 Thus pc* + Bcz ~ N(/p1*, &c)
and thus f# ~ log-normal(p14, &c)
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Figure 3-2: prior predictive distribution of fLc for several values of and ~
3.5.9 Choosing c' and AC
As P(pc; cc) is always unimodal, the only consideration we choosing CC is that if it is
too large, the mean of P(pC; cc) will shift too much as Je changes. We plotted the
distribution of P(p'; cC) for several values of p and &c. From these plots, it seems
that setting cc = 1 gives a distribution of P(p; cC) that does not shift too much with
-C
To choose AC, we once again need to encourage #c to be small. We found that a
value of AC = 1, along with cC = 1, resulted in unimodal distributions for P(EI|c, Ac).
Choosing a prior for 44"sse
For the other parameters, we had to choose their corresponding hyperparmeters care-
fully because we desired that the prior of those parameters be unimodal. However
we don't run into such problems with choosing 4""', as we know if the prior on
g(t; s, a, b, c) is unimodal, g* (g; s, a, b, c) will be unimodal regardless of the value of
4""t*e. Then, we are free to estimate the hyperparameter for 4"*ose from the data.
We can do so through maximum-likelihood estimation, jointly maximum all variables
not conditioned on in the posterior, and seeing what the value of A""' is.
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Figure 3-3: prior predictive distribution of over curves for several values of X
3.6 Plots of prior patient curve distributions
Having established priors on all parameters by choosing values for the parameters, we
have a prior predictive distribution (P(a, b, c; a, X) where a denotes the hyperparam-
eters. Thus, we can plot the induced prior predictive distribution over 'true' curves,
P(g(t); s, a, b, c,1 ), which we do so below, for several values of X. Note that the
curves are all centered approximately the same; the mode of the curve distribution is
the same regardless of X. However, their spread differs.
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Chapter 4
Curve Prediction with Model
4.1 Bayesian Inference
The Bayesian approach [3]is simple and concise, and after training, ultimately allows
us to generate, for a test sample X, a distribution over curves g(t; s, a, b, c, X). In
the previous section, we have described a joint distribution over all parameters and
data, P(X, 0; a), where X denotes the observed function value points, and we have
integrated out the latent patient curve parameters a, b, c. A patient's curve parameters
depend on no other variables besides the parameters 0, if none of the patient's function
values are observed, as will be the case when performing prediction. Thus for a test
sample, we need to determine P(; X, a). Once we have that, we can directly calculate
P(d; X, a) = P(d; 0) * P(0 : X, a), and likewise for b and .
To perform the actual inference, we use the standard Metropolis-hastings method[4],
with our proposals consisting of cycling through the variables of the distribution and
proposing to add a normally distributed noise to it. We use the PYMC package.
4.2 Simulation Results
To show that we can perform posterior inference to extract the posterior distribution
of the model parameters Ba, Bb, Be, we simulated data, fixing Ba, Bb, Be. We simu-
lated 2 different sets of variables. In both cases, we set Ba = -1, Bb = 1, Bc = 2.
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Also, we assume the presence of only 1 covariate, and generated 15 covariates equally
spaced in the interval (-2,2) to use as the data X.
4.2.1 Simulating latent variables a, b, c
In the first scenario, we set #' = #6 = 0.5 and #c = 0.2, and for each Xj, generated
a , bi, ci from the distribution specified by the model. For example, we generated
ai from a Beta(Ba * Xj, #4) distribution. This model does not contain any actual
function values, since a, b, c are directly simulated/observed. To perform inference,
we used the same model, fixing 4 , 6, 0' to the values used to generate aj, bi, ci, and
inferred the distribution of P(Balai, bi, c, #a, #6, 0c, Xi), and likewise for B and Bc.
4.2.2 Simulating data points g*(t)
In the second scenario, we fix the #a, #6, 0' and Ba, Bb, Be as before. However, we do
not simulate a, b, c directly. Rather, we picked a set of times ti . . . tn, and for each of
the 15 patients, simulated gf(tj) according to the model. We set #"ie = 0.1. That
is, we first simulate aj, bi, ci and once those are determined, simulate gi'(tj) for each
time point tj. To perform inference of Ba, Bb, Bc, we once again assume we know
all noise parameters #a, #6, 0, 0"'se, and perform sampling to get the distribution of
P(Ba{g 97(ty)}, 44a, #6, #c, #"*ise, X,)
4.3 Biasedness of model
From the previous 2 sections, we see that the posterior distributions for Ba, Bb, Bc
is actually not centered correctly. To diagnosis this, I created a simplified model to
isolate what was going wrong. This is basically the part of the model that predicts a:
f1(X) = (4.1)
= 1+ e-
pi= faQafp",+ Bax ) (4.2)
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ai ~ Beta pi, #a) (4.3)
B ~ U(-oo, oo) (4.4)
I generate 50 xi's centered symmetrically about 0. I set B, = 1. I obtain the
corresponding ai's, with no noise, so that ai = pt4. I assume #' is fixed. I do sampling
to infer P(Balaj, xi, #4). There is only 1 unobserved variable in this distribution - Ba.
The distribution of P(Balai, xi, #a) changes as I vary #'. The distribution is centered
correctly at 1.0 for small #'. The larger #' is, the more offset the distribution is. See
the following plot.
The reason for this biasedness is that if we fix #' to be large, the distribution for
ai will be U-shaped. I think posterior for Ba is centered at 0 if #a is close to 1 because
when the distribution of a; is U-shaped, it pays to be off in the predictions.
The solution is to give zero probability to situations where the distribution of
P(a; pLa, #4) is U-shaped. This can be done by parameterizing the Beta distributions
for a and b differently. Before, #' represented the proportion of the maximum possible
variance for a Beta distribution with the specified mean. Now, we should let #'
represented the proportion of the maximum possible variance for a Beta distribution
with the specified mean, such that the distribution is still unimodal. Hopefully this
quantity can be calculated analytically.
4.3.1 Applicability of Model to Real Data
Now that we have parameterized patient function curves, we can explore the rela-
tionship between various covariates and curve parameters. Recall from previous plots
that the covariates that seem to affect the curve shape the most are age and the
pre-treatment function level. On the following few pages, for each of the 3 side effect
function values, and for each of treatments, and for each of those 2 covariates, we
make 4 scatter plots. For each scatter plot, the x-axis is the covariate, and the y-axis
is 1 of 4 curve parameters: a, b, c, and also the quantity a + (1 - a)b, which is equal to
the total initial drop in function value, relative to the pre-treatment function value.
This last quantity is labelled as 'drop' in the scatter plots. Trends in these scatter
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plots would lead us to believe that the coefficients in the generalized linear models
for the a, b, c parameters would be non-zero.
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